Company Overview
Company Type: Private Company
Website: www.engene.com
Number of Employees: -
Year Founded: 1999
Total Amount Raised (CAD mm)†: 24.14
Total Rounds of Funding**:5
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
enGene, Inc. develops a mucosal immunotherapy platform for treating inflammatory bowel disease and diabetes. The company develops a non-integrating biopolymer-based nucleotide (DNA and siRNA) delivery technology that facilitates localized delivery of immune-modulating proteins to the intestinal mucosa for treating various immune disorders. It also provides a platform technology that impacts diseases of mucosal tissues, such as gastrointestinal tract, lung, and bladder, as well as provides systemic release of proteins from the gut for the treatment of diabetes, anemia, and hemophilia. The company was incorporated in 1999 and is based in Saint-Laurent, Canada with an additional office location in Waltham, Massachusetts.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Nichols, Alex 
President & COO
Brown, John C.
Co-Founder and Member of Scientific Advisory Board
Cheung, Anthony T.
Co-Founder, Corporate Secretary, CTO & Executive Director
Sullivan, James C.
Chief Scientific Officer
Podrebarac, Theresa 
Chief Medical Officer
Tan, Sharon 
VP of Project Management & Head of Program Management
Erickson, Paul
Non-Executive Director

Key Board Members
Name
Title
Wood, L. Jack
Chairman
Brown, John C.
Co-Founder and Member of Scientific Advisory Board
Cheung, Anthony T.
Co-Founder, Corporate Secretary, CTO & Executive Director
Gannon, Steven R.
Independent Director
Robbins, Paul D.
Chairman of Scientific Advisory Board
D’Haens, Geert 
Member of Clinical Advisory Board
Dhal, Marshall A.
Member of Scientific Advisory Board
Dunlop, A. Sinclair
Observer
Feagan, Brian Gordon 
Member of Clinical Advisory Board
Fedorak, Richard N.
Member of Clinical Advisory Board
Gargiulo, Francis J.
Non Executive Director
Glickman, Richard M.
Non-Executive Director


Primary Industry Classification
Biotechnology


Primary Office Location
7171 Rue Frederick Banting | Saint-Laurent, QC | H4S 1Z9 | Canada
Phone: 514 332 4888   Fax: 604 221 4369

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
Investment Coverage
Fonds de solidarité FTQ
Aug-01-2013
Minority
-
Series B
-
Forbion Capital Partners B.V.
Aug-01-2013
Minority
-
Series B
Marco Boorsma, Sander Van Deventer
Lumira Ventures
Aug-01-2013
Unknown
-
Series B
Brian Underdown, Richard Glickman
Pharmstandard International S.A.
Aug-01-2013
Unknown
-
Series B
-
Masa Inc., Investment Arm
Mar-17-2008
Unknown
-
Series A
-

Prior Investors
SAAD Investments Company Limited


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Forbion European Acquisition Corp. (NasdaqGM:FRBN) (Pending)
Forbion European Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to identify opportunities in the life sciences industry in Europe. The company was incorporated in 2021 and is based in Wilmington, Delaware.

United States and Canada
Asset Management and Custody Banks
-
136.00
2.00


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
May-17-2023
-
Merger/Acquisition
Buyer
Forbion European Acquisition Corp. (NasdaqGM:FRBN)
enGene, Inc.
Forbion European Growth Sponsor FEAC I B.V.,Citadel Advisors LLC,Highbridge Capital Management, LLC,Forbion Growth Opportunities Fund I Coöperatief U.A.
111.00
Mar-31-2017
Mar-31-2017
Private Placement
Target
enGene, Inc.
Pharmstandard International S.A.

0.84
Jan-31-2017
Jan-31-2017
Private Placement
Target
enGene, Inc.
Pharmstandard International S.A.

0.01
Jan-06-2015
Jan-06-2015
Private Placement
Target
enGene, Inc.
Forbion Capital Partners B.V. Buyer Funds:Forbion Capital Fund III

-
Aug-01-2013
Jan-26-2015
Private Placement
Target
enGene, Inc.
Lumira Ventures,Forbion Capital Partners B.V.,Fonds de solidarité FTQ,Pharmstandard International S.A. Buyer Funds:Merck Lumira Biosciences Fund

10.86
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
May-17-2023
M&A Transaction Announcements
enGene, Inc. entered into a definitive business combination agreement to acquire Forbion European Acquisition Corp. (NasdaqGM:FRBN) from a group of shareholders in a reverse merger transaction for an enterprise value of approximately $110 million.
Feb-02-2023
Executive/Board Changes - Other
enGene, Inc. Appoints Alex Nichols as President and Chief Operating Officer
Mar-17-2022
Executive/Board Changes - Other
enGene, Inc. Appoints James C. Sullivan as Chief Scientific Officer
Feb-08-2022
Product-Related Announcements
enGene, Inc. Announces Positive Preliminary Phase 1/2 Data with EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
May-27-2021
Product-Related Announcements
enGene Inc. Announces First-In-Human Dosing of EG-70 for Treatment of Non-Muscle Invasive Bladder Cancer in Phase 1/2 Clinical Trial

M&A Advisors
Blake, Cassels & Graydon LLP, Morgan Stanley & Co. LLC, Morgan, Lewis & Bockius LLP


Advisors
M&A Advisors
Blake, Cassels & Graydon LLP, Morgan Stanley & Co. LLC, Morgan, Lewis & Bockius LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 21, 2023 05:44 AM
enGene, Inc.
enGene Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
27
GlobalData

Sep 21, 2023 04:13 AM
enGene, Inc.
enGene Inc
Reports
55
GlobalData

Sep 15, 2023 12:08 AM
enGene, Inc.
enGene Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
24
GlobalData

Jun 15, 2023 02:08 AM
enGene, Inc.
enGene Inc
Reports
54
GlobalData

Jun 09, 2023 01:02 AM
enGene, Inc.
enGene Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
23
GlobalData

Mar 14, 2023 01:29 AM
enGene, Inc.
enGene Inc
Reports
40
GlobalData

Mar 10, 2023 03:27 AM
enGene, Inc.
enGene Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
24
GlobalData

Dec 16, 2022 02:42 AM
enGene, Inc.
enGene Inc
Reports
45
GlobalData

Dec 10, 2022 12:40 AM
enGene, Inc.
enGene Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
22
GlobalData

Sep 21, 2022 06:27 AM
enGene, Inc.
enGene Inc
Reports
45


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Interleukin-10 (Future), Meal-responsive Insulin (Future)

Key Board Members Details
Name
Title
Phone
Fax
Email
Wood, L. Jack
Chairman
514 332 4888
604 221 4369
-
Brown, John C.
Co-Founder and Member of Scientific Advisory Board
514 332 4888
604 221 4369
-
Cheung, Anthony T.
Co-Founder, Corporate Secretary, CTO & Executive Director
514 332 4888
604 221 4369
acheung@engeneinc.com
Gannon, Steven R.
Independent Director
514 332 4888
604 221 4369

Robbins, Paul D.
Chairman of Scientific Advisory Board
514 332 4888
604 221 4369
-
D’Haens, Geert 
Member of Clinical Advisory Board
514 332 4888
604 221 4369

Dhal, Marshall A.
Member of Scientific Advisory Board
514 332 4888
604 221 4369
-
Dunlop, A. Sinclair
Observer
514 332 4888
604 221 4369
sdunlop@mlsvfund.com
Feagan, Brian Gordon 
Member of Clinical Advisory Board
514 332 4888
604 221 4369

Fedorak, Richard N.
Member of Clinical Advisory Board
514 332 4888
604 221 4369
-
Gargiulo, Francis J.
Non Executive Director
514 332 4888
604 221 4369
-
Glickman, Richard M.
Non-Executive Director
514 332 4888
604 221 4369

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Nichols, Alex 
President & COO
514 332 4888
604 221 4369

Brown, John C.
Co-Founder and Member of Scientific Advisory Board
514 332 4888
604 221 4369
-
Cheung, Anthony T.
Co-Founder, Corporate Secretary, CTO & Executive Director
514 332 4888
604 221 4369
acheung@engeneinc.com
Sullivan, James C.
Chief Scientific Officer
514 332 4888
604 221 4369

Podrebarac, Theresa 
Chief Medical Officer
514 332 4888
604 221 4369

Tan, Sharon 
VP of Project Management & Head of Program Management
514 332 4888
604 221 4369

Erickson, Paul
Non-Executive Director
514 332 4888
604 221 4369
-
* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
